VIASYS Healthcare Inc. (NYSE:VAS) ("VIASYS") and Hoffman
Laboratories, LLC, announced today that VIASYS has acquired the
assets of Hoffman Laboratories, LLC - a company that develops
products targeted to the sleep therapeutic market. Randy Thurman,
Chairman, President and Chief Executive Officer, VIASYS Healthcare
Inc., commented, "With this acquisition, VIASYS is increasing its
presence in the global sleep therapy market. We believe sleep
therapy is the fastest growing market segment in the global
respiratory market. VIASYS is already a market leader in the sleep
diagnostics business, with well established brands such as JaegerTM
and SENSORMEDICS�. We expect that Hoffman Laboratories� expertise
in CPAP and noninvasive ventilation design will enhance the VIASYS
global product offering. We believe this acquisition is a key step
following the establishment earlier this year of the VIASYS Sleep
Diagnostics and Therapy business as a separate operating entity
focused on this opportunity." Based in Chatsworth, California,
Hoffman Laboratories designed, manufactured, marketed, and sold
Continuous Positive Airway Pressure (CPAP) devices and patient
interfaces. Hoffman Laboratories offered home health care providers
and sleep diagnostics laboratories the BreatheX�, the first
self-contained, battery-powered, �wearable CPAP.� BreatheX�
represents a truly innovative, portable solution to meet the needs
of patients receiving treatment for Obstructive Sleep Apnea. Ed
Pulwer, Group President, VIASYS Respiratory Care, commented, �We
believe that the acquisition of Hoffman Laboratories and the
strength of its CPAP device technology is an outstanding compliment
to our acquisition earlier this year of Tiara Medical Systems. We
believe that we have brought together companies with VIASYS that
have extensive expertise in the development of core technologies
essential to CPAP devices, noninvasive ventilators, portable
ventilators and patient interfaces. The Hoffman acquisition
demonstrates VIASYS Respiratory Care�s commitment to expand its
presence in the sleep therapy market and maintain its leadership
position in the mechanical ventilation market. Rebecca Mabry,
General Manager, Sleep Diagnostics and Therapy, will be responsible
for managing the acquired business.� Under the terms of the
acquisition agreement, VIASYS acquired the assets of Hoffman
Laboratories, LLC, through its subsidiary, VIASYS Sleep Solutions
LLC. VIASYS financed the acquisition with cash and borrowings under
its revolving credit facility. Additional terms of the transaction
are not being disclosed at this time. ABOUT VIASYS HEALTHCARE INC.
VIASYS Healthcare Inc. is a global, research-based medical
technology company focused on respiratory, neurology, medical
disposable and orthopedic products. VIASYS products are marketed
under well-recognized trademarks including, among others, AVEA�,
BEAR�, BIRD�, CORFLO�, CORPAK�, CORTRAK�, EME�, GRASON-STADLER�,
JAEGER�, LYRA�, MEDELEC�, MICROGAS�, NAVIGATOR�, NICOLET�,
NicoletOne�, PULMONETIC�, SENSORMEDICS�, TECA�, TECOMET�, VELA� and
VMAX�. VIASYS is headquartered in Conshohocken, PA, and its
businesses are conducted through its Respiratory Care, NeuroCare,
MedSystems and Orthopedics business units. More information can be
found at http://www.viasyshealthcare.com. This news release
includes forward-looking statements within the meaning of the "Safe
Harbor" provisions of Private Securities Litigation Reform Act of
1995 regarding VIASYS' product offering, VIASYS' ability to compete
in the sleep market, VIASYS' presence in and commitment to the
sleep therapy market, the strategic impact of acquiring Hoffman
Laboratories, and the growth of (and market opportunity in) the
sleep therapy market. These forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including important factors that could delay, divert, or change the
expectations for VIASYS' products and could cause actual outcomes
and results to differ materially from current expectations. These
factors include, among other things, market factors, internal
research and development initiatives, partnered research and
development initiatives, competitive and new product development,
marketing initiatives, sales and distribution risks, the continued
growth of the sleep therapy market, the successful integration of
the Hoffman Laboratories business into VIASYS� existing sleep
business, governmental regulations and legislation, patent
positions, litigation and the inability to achieve the anticipated
benefits of this transaction. For further details and a discussion
of other risks and uncertainties that may change VIASYS'
expectations, please see VIASYS' annual report on Form 10-K for the
year ended January 1, 2006, which is on file with the Securities
and Exchange Commission. VIASYS undertakes no obligation to
publicly update this forward-looking statement, whether as a result
of new information, future events, or otherwise. VIASYS Healthcare
Inc. (NYSE:VAS) ("VIASYS") and Hoffman Laboratories, LLC, announced
today that VIASYS has acquired the assets of Hoffman Laboratories,
LLC - a company that develops products targeted to the sleep
therapeutic market. Randy Thurman, Chairman, President and Chief
Executive Officer, VIASYS Healthcare Inc., commented, "With this
acquisition, VIASYS is increasing its presence in the global sleep
therapy market. We believe sleep therapy is the fastest growing
market segment in the global respiratory market. VIASYS is already
a market leader in the sleep diagnostics business, with well
established brands such as Jaeger(TM) and SENSORMEDICS(R). We
expect that Hoffman Laboratories' expertise in CPAP and noninvasive
ventilation design will enhance the VIASYS global product offering.
We believe this acquisition is a key step following the
establishment earlier this year of the VIASYS Sleep Diagnostics and
Therapy business as a separate operating entity focused on this
opportunity." Based in Chatsworth, California, Hoffman Laboratories
designed, manufactured, marketed, and sold Continuous Positive
Airway Pressure (CPAP) devices and patient interfaces. Hoffman
Laboratories offered home health care providers and sleep
diagnostics laboratories the BreatheX(R), the first self-contained,
battery-powered, "wearable CPAP." BreatheX(R) represents a truly
innovative, portable solution to meet the needs of patients
receiving treatment for Obstructive Sleep Apnea. Ed Pulwer, Group
President, VIASYS Respiratory Care, commented, "We believe that the
acquisition of Hoffman Laboratories and the strength of its CPAP
device technology is an outstanding compliment to our acquisition
earlier this year of Tiara Medical Systems. We believe that we have
brought together companies with VIASYS that have extensive
expertise in the development of core technologies essential to CPAP
devices, noninvasive ventilators, portable ventilators and patient
interfaces. The Hoffman acquisition demonstrates VIASYS Respiratory
Care's commitment to expand its presence in the sleep therapy
market and maintain its leadership position in the mechanical
ventilation market. Rebecca Mabry, General Manager, Sleep
Diagnostics and Therapy, will be responsible for managing the
acquired business." Under the terms of the acquisition agreement,
VIASYS acquired the assets of Hoffman Laboratories, LLC, through
its subsidiary, VIASYS Sleep Solutions LLC. VIASYS financed the
acquisition with cash and borrowings under its revolving credit
facility. Additional terms of the transaction are not being
disclosed at this time. ABOUT VIASYS HEALTHCARE INC. VIASYS
Healthcare Inc. is a global, research-based medical technology
company focused on respiratory, neurology, medical disposable and
orthopedic products. VIASYS products are marketed under
well-recognized trademarks including, among others, AVEA(R),
BEAR(R), BIRD(R), CORFLO(R), CORPAK(R), CORTRAK(R), EME(R),
GRASON-STADLER(R), JAEGER(R), LYRA(R), MEDELEC(R), MICROGAS(R),
NAVIGATOR(R), NICOLET(R), NicoletOne(TM), PULMONETIC(TM),
SENSORMEDICS(R), TECA(R), TECOMET(TM), VELA(R) and VMAX(R). VIASYS
is headquartered in Conshohocken, PA, and its businesses are
conducted through its Respiratory Care, NeuroCare, MedSystems and
Orthopedics business units. More information can be found at
http://www.viasyshealthcare.com. This news release includes
forward-looking statements within the meaning of the "Safe Harbor"
provisions of Private Securities Litigation Reform Act of 1995
regarding VIASYS' product offering, VIASYS' ability to compete in
the sleep market, VIASYS' presence in and commitment to the sleep
therapy market, the strategic impact of acquiring Hoffman
Laboratories, and the growth of (and market opportunity in) the
sleep therapy market. These forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including important factors that could delay, divert, or change the
expectations for VIASYS' products and could cause actual outcomes
and results to differ materially from current expectations. These
factors include, among other things, market factors, internal
research and development initiatives, partnered research and
development initiatives, competitive and new product development,
marketing initiatives, sales and distribution risks, the continued
growth of the sleep therapy market, the successful integration of
the Hoffman Laboratories business into VIASYS' existing sleep
business, governmental regulations and legislation, patent
positions, litigation and the inability to achieve the anticipated
benefits of this transaction. For further details and a discussion
of other risks and uncertainties that may change VIASYS'
expectations, please see VIASYS' annual report on Form 10-K for the
year ended January 1, 2006, which is on file with the Securities
and Exchange Commission. VIASYS undertakes no obligation to
publicly update this forward-looking statement, whether as a result
of new information, future events, or otherwise.
Viasys Healthcare (NYSE:VAS)
Historical Stock Chart
From May 2024 to Jun 2024
Viasys Healthcare (NYSE:VAS)
Historical Stock Chart
From Jun 2023 to Jun 2024